Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases
July 6, 2020
By Frank Vinluan
Bristol Myers Squibb likes what it sees from the immune cell research of Dragonfly Therapeutics so far—enough to pay $55 million to add multiple sclerosis and neuroinflammation to their ongoing partnership.
The alliance came to New York-based Bristol via its acquisition of Celgene last year. The original 2017 deal covered the development of up to four blood cancer drugs. The partnership expanded the following year to cover four more drug targets. As of last November, Celgene had opted to exercise rights to three of the Waltham, MA-based biotech’s drug candidates.
Full report can be read here